GV has notched six billion-dollar exits since its inception. GV has yet to make a new seed investment in 2016 YTD.
Bill Maris founded GV in 2009 and, since then, the Alphabet-backed venture arm has gone on to become the most prolific investor in corporate venture capital. As he prepares to leave for new pastures, we dug into the data on the evolution of GV under Maris. Here’s the data.
GV dials back on seed
We’ve previously highlighted how, in recent years, GV was not only the most active corporate VC but among the most active VCs period at the seed-stage. In December 2015, Bill Maris commented,
“We moved away from seed-stage investing … I think there’s less opportunity here.”
The reality is that GV had already been dialing back on its seed investing program significantly. According to CB Insights data, GV completed 78% fewer new seed investments in 2015 on a year-over-year basis and has completed zero seed deals in 2016 YTD.
The reduced seed activity reflects in GV’s overall deal pace as our data shows that GV made 46% fewer new bets in 2015 than in 2014. In the first half of 2016, GV made 31% more deals than in the same period in 2015, but 30% fewer deals than in H1 2014.
GV vs. Google Capital vs. Google
One point that’s come up more is that GV is no longer Alphabet’s only investment vehicle. Rather, growth investments done through Google Capital and direct minority investments by Google in the likes of Space X and Magic Leap have increased in the last two years. We take a look at that below.
GV’s top exits
Since its inception, GV has notched 5 $1B+ exits, its latest and largest by valuation at time of exit being Jet’s acquisition by Walmart. We tallied up GV’s top 10 exits to date and its point of entry, which also include OnDeck Capital, Hubspot and Editas among others.
|Company||Valuation at time of exit||GV Stage of Entry||Year|
|Jet.com||$3.3B||Convertible Note (Post Series A)||2016|
|Nest Labs||$3.2B||Series C||2014|
|OnDeck Capital||$1.32B||Series D||2014|
|Climate Corp||$1B||Series B||2013|
|SilverSpring Networks||$754M||Series D||2013|
|Editas Medicine||$571M||Series B||2016|
|Foundation Medicine||$489M||Series A||2013|
Looking for more data on GV? Sign up free for the CB Insights Venture Capital Database.
This report was created with data from CB Insights’ emerging technology insights platform, which offers clarity into emerging tech and new business strategies through tools like:
- Earnings Transcripts Search Engine & Analytics to get an information edge on competitors’ and incumbents’ strategies
- Patent Analytics to see where innovation is happening next
- Company Mosaic Scores to evaluate startup health, based on our National Science Foundation-backed algorithm
- Business Relationships to quickly see a company’s competitors, partners, and more
- Market Sizing Tools to visualize market growth and spot the next big opportunity